Zhejiang Garden Biopharmaceutical Co Ltd

Zhejiang Garden Biopharmaceutical Co Ltd maintains a debt-to-equity ratio of 0.5, indicating a relatively balanced capital structure with moderate leverage. The company's liquidity position is assessed as medium, with a current ratio of 2.52, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is low at 27.96 million CNY, which may constrain its ability to reinvest or return capital to shareholders without external financing.

Profitability metrics show a return on equity (ROE) of 8.74% and a return on assets (ROA) of 5.27%, both below the typical thresholds for high-margin pharmaceutical firms. These figures suggest the company is generating returns, but not at a level that would be considered exceptional within the industry.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks, particularly in the Chinese market.

Growth appears to be constrained, with no clear indication of revenue acceleration in the near term. The company's capital expenditures are negative at -361.96 million CNY, indicating asset disposals or a reduction in investment, which may signal a strategic shift or financial prudence.

The risk assessment highlights a liquidity risk due to negative net cash after subtracting total debt. While dilution risk is currently low, the company's reliance on external financing could increase if free cash flow remains weak. No recent filings or transcripts indicate material changes in strategy or operations.

No recent events, such as earnings calls, regulatory filings, or press releases, have been disclosed that would indicate a material shift in the company's strategic direction or financial health.